Dual-Targeted CAR T-Cell Therapy Leads to Very High Response Rates in Relapsed or Refractory Multiple Myeloma.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 53
- Publication type:
- Article
Works matching IS 21641153 AND DT 2020 AND VI 10 AND IP 1
Results: 23
1
2
Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 52
- Publication type:
- Article
3
Investigational BET Inhibitor, CPI-0610, Promotes Responses in Myelofibrosis.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 51
- Publication type:
- Article
4
Nivolumab Monotherapy as Bridge to Transplant in Patients with Relapsed or Refractory Hodgkin Lymphoma.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 50
- Publication type:
- Article
5
Tazemetostat, First-in-Class EZH2 Inhibitor, Shows Impressive Activity in Relapsed or Refractory Follicular Lymphoma.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 49
- Publication type:
- Article
6
All-Oral Time-Limited Combination Treatment for CLL or SLL Shows Early Impressive Efficacy.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 48
- Publication type:
- Article
7
Investigational Oral Form of Azacitidine Improves Survival Maintenance Therapy in Patients with Acute Myeloid Leukemia.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 47
- Publication type:
- Article
8
First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 46
- Publication type:
- Article
9
Zanubrutinib, Next-Generation BTK, Leads to Impressive Responses in Patients with CLL or SLL.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 45
- Publication type:
- Article
10
Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy Prevents Cytokine Release Syndrome.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 44
- Publication type:
- Article
11
Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 43
- Publication type:
- Article
12
Xtandi Now Approved for Metastatic Castration-Sensitive Prostate Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 42
- Publication type:
- Article
13
Lynparza Indicated for Maintenance Treatment of Metastatic Pancreatic Cancer with BRCA Mutation.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 42
- Publication type:
- Article
14
Keytruda Indicated for BCG-Unresponsive High-Risk, Non-Muscle Invasive Bladder Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 41
- Publication type:
- Article
15
Padcev First-in-Class Targeted Therapy FDA Approved for Advanced or Metastatic Urothelial Carcinoma.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 41
- Publication type:
- Article
16
Enhertu a Novel Dual-Targeted Therapy Approved for Metastatic HER2-Positive Breast Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 41
- Publication type:
- Article
17
Ayvakit First Targeted Therapy Approved for Gastrointestinal Stromal Tumors with PDGFRA Mutations.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 40
- Publication type:
- Article
18
Tazverik First FDA-Approved Drug for Advanced Epithelioid Sarcoma Ineligible for Resection.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 40
- Publication type:
- Article
19
Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 32
- By:
- Publication type:
- Article
20
Clostridium difficile Infection Management in Adults Undergoing Stem-Cell Transplant.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 28
- By:
- Publication type:
- Article
21
Inadequate Transdermal Patch Absorption in a Patient with Scleroderma Associated with Graft-versus-Host Disease.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 24
- By:
- Publication type:
- Article
22
Subcutaneous versus Intravenous Granulocyte Colony-Stimulating Factor to Enhance Neutrophil Engraftment in Patients Undergoing Hematopoietic Stem-Cell Transplant.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 13
- By:
- Publication type:
- Article
23
Hypersensitivity Rates in Pediatric Patients Receiving Intravenous or Intramuscular Asparaginase Agents.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2020, v. 10, n. 1, p. 7
- By:
- Publication type:
- Article